Application of homovanillic acid in preparation of antiplatelet and antithrombotic drugs

A high vanillic acid, anti-platelet technology, applied in the field of medicine, can solve the problems of less research on pharmacological effects, anti-platelet and/or thrombosis drug effects have not been reported, etc.

Active Publication Date: 2021-06-22
INST OF MATERIA MEDICA AN INST OF THE CHINESE ACAD OF MEDICAL SCI
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patented technology uses various inducing plasma modeling techniques such as those described earlier with regard to platelets. It shows how these methods have shown promising benefits over other existing treatments like aspirin but they also show some limitations when used alone due to their ability to block certain substances involved in blood clotting process altogether. Therefore, this new method offers an alternative way to reduce unwanted side reactions caused by platelet activators called platelet factors.

Problems solved by technology

This patented technical problem addressed in this patents relates to finding new ways to treat disorders associated with excessively activating clotting factors called platelets due to abnormal cell growth such as those seen during heart attacks and strokes. Current methods involve administered agents like acute care medications aiming to stop them down quickly without harmful side reactions.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of homovanillic acid in preparation of antiplatelet and antithrombotic drugs
  • Application of homovanillic acid in preparation of antiplatelet and antithrombotic drugs
  • Application of homovanillic acid in preparation of antiplatelet and antithrombotic drugs

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0035] Experimental example 1. The inhibitory effect of homovanillic acid on platelet aggregation in vitro.

[0036] Male SD rats with a body weight of 200-220 g were selected for the experiment, anesthetized with chloral hydrate, blood was taken from the abdominal aorta, and 3.8% sodium citrate solution 1:9 (anticoagulant: blood) was added for anticoagulation, 1200rpm, room temperature ( 23°C) for 10 minutes. After the centrifugation, carefully absorb the upper layer with a pipette gun to avoid sucking blood cells. The upper layer obtained is PRP (platelet-rich), and the remaining lower layer is centrifuged again at 3000 rpm at room temperature (23°C) for 10 minutes. Pipette the upper layer carefully, resulting in PPP (platelet-poor). Take PRP and centrifuge at room temperature (23°C), 1800rpm, 10min, discard the supernatant, obtain platelet assay, add platelet resuspension (7.7772mg / mL NaCl, 0.048mg / mL NaCl 2 HPO 4 , 0.217mg / mL KCL, 1.008mg / mL NaHCO 3 , 0.9mg / mL Glucose, ...

experiment example 2

[0039] Experimental example 2. The inhibitory effect of homovanillic acid on platelet aggregation in vivo.

[0040] Male SD rats, weighing 200-220g, were randomly divided into 6 groups, with 5 rats in each group. The blank control group was given 0.5% CMC-Na (100g / mL), once in the morning and once in the evening, and the aspirin group: 100mg / kg in the morning and evening. Clopidogrel group: 30mg / kg, once in the morning and evening, high vanillic acid low dose group: 10mg / kg, once in the morning and evening, high vanillic acid medium dose group: 30mg / kg, once in the morning and evening, high vanillic acid high Dosage group: 100mg / kg, once in the morning and once in the evening, after continuous administration for 5 days, platelet aggregation was measured on the 6th day. Prepare PRP and PPP according to the above-mentioned experimental method, and use the turbidimetric method to measure the platelet aggregation rate under the condition of 37 ° C by LG-PABER-I semi-automatic coag...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an application of homovanillic acid in medicines for resisting platelets, resisting thrombus and preventing and treating diseases related to platelet activation and thrombosis. The platelet activation and thrombosis related diseases refer to diseases caused by artery and/or venous thrombosis, including ischemic cerebral apoplexy, acute/chronic myocardial infarction, acute pulmonary embolism and peripheral vascular thrombotic diseases. In-vivo and in-vitro experimental studies show that homovanillic acid can significantly inhibit platelet aggregation reactions induced by different inducers, and exerts anti-platelet and anti-thrombosis effects. The homovanillic acid can be used for preparing medicines for preventing and treating platelet aggregation and thrombosis, adverse reactions are reduced, and a safe, effective and economical solution is provided for treatment and prevention of thrombotic diseases.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Owner INST OF MATERIA MEDICA AN INST OF THE CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap